A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia

• Published in: Clinical and experimental rheumatology Vol. 13 Suppl 13; p. S201
• Main Authors: Ballarè, M, Bobbio, F, Poggi, S, Bordin, G, Bertoncelli, M C, Catania, E, Monteverde, A
• Format: Journal Article
• Language: English
• Published: Italy 01-11-1995
• Subjects: Antirheumatic Agents - therapeutic use; Cryoglobulinemia - complications; Cryoglobulinemia - drug therapy; Cryoglobulinemia - virology; Cyclosporine - therapeutic use; Female; Hepacivirus - genetics; Humans; Italy; Middle Aged; Pilot Projects; Purpura - complications; Purpura - drug therapy; RNA, Viral - analysis; Italy
• ISSN: 0392-856X

To evaluate the effect of cyclosporine in the treatment of type II mixed cryoglobulinemia, after the failure of more conventional therapies.
Two patients with type II mixed cryoglobulinemia associated with chronic HCV infection, purpura, liver disease, and sensitive/motor neuropathy were treated with cyclosporine (2.5 mg/Kg/b.w.), after their failure to respond to treatment with corticosteroid, immunosuppressive drugs, interferon, and plasmapheresis.
In both patients an improvement in the clinical manifestations (purpura and peripheral neuropathy), laboratory results (serum transaminases and cryocrit), and liver histology was seen, as well as the disappearance of bone marrow B-cell lymphoproliferation.
Cyclosporine may be useful in the treatment of type II mixed cryoglobulinemia with prominent autoimmune clinical manifestations, although further studies are needed to better define the selection of patients.